Screener
NeoGenomics NEO R&D
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001077183-26-000059
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| GROSS PROFIT | 91,878 | 77,258 | 172,742 | 150,504 |
| Operating expenses: | ||||
| General and administrative | 63,613 | 71,747 | 129,354 | 139,954 |
| Research and development | 10,761 | 9,023 | 20,295 | 19,204 |
| Sales and marketing | 27,275 | 24,075 | 51,105 | 46,758 |
| Impairment charges (Note 5) | — | 20,041 | — | 20,041 |
| Total operating expenses | 101,649 | 124,886 | 200,754 | 225,957 |
| LOSS FROM OPERATIONS | (9,771) | (47,628) | (28,012) | (75,453) |
Item 1. Financial Statements (unaudited)
FAQ
- What is NeoGenomics's R&D?
- NeoGenomics (NEO) reported R&D of $10.76M in Q2 2026.
- How has NeoGenomics's R&D changed year-over-year?
- NeoGenomics's R&D increased by 19.3% year-over-year, from $9.02M to $10.76M.
- What is the long-term trend for NeoGenomics's R&D?
- Over 4 years (2021 to 2025), NeoGenomics's R&D has grown at a 14.1% compound annual growth rate (CAGR), from $21.87M to $37.08M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about NeoGenomics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude